Healthcare Stocks Can Help Lower Inflation’s Fever

Video Description

Demand for healthcare products tends to stay resilient during periods of inflation. That’s good news for equity investors in the sector.


I think one of the benefits of investing in healthcare is that these companies have inelastic demand. If you need a new heart valve, inflation isn’t going to impact that decision.

We think healthcare companies are quite resilient during periods of inflation because their products are not substitutable and they deliver innovation. So an example of that would be the rise of robotics in surgery. This particular technology allows patients to get out of the hospital faster. There are less complications associated with these surgeries. And so really it’s a win-win. It’s a win for patients—they get out of the hospital sooner, they don’t have the same side effects. It’s a win for hospitals—they’re turning over their beds a lot quicker, they’re running a more efficient operation. So, in periods of inflation, we think that products like these actually have increased demand because companies want to drive more efficient results.

One of the things that’s often misunderstood about healthcare is this notion that it is purely a defensive sector. In our view, that simply just isn’t true. It is defensive, but it’s also offensive. And it’s offensive in terms of the innovation that’s happening. It spans everything from gene sequencing that’ll help us predict cancer through a blood test, all the way through to new types of drugs like gene therapy or mRNA vaccines that were very helpful during COVID.

But one of the ways we differentiate ourselves is that we don’t try and predict clinical trial success. It’s really hard to get a drug all the way through human trials and onto the market. The stats are actually 8%, meaning 92% of the time the company’s going to fail. So, with those low odds, it’s really hard to figure out which ones will succeed.

What we’re focused on as we think out over the long term, in terms of interesting technologies, would be the rise of things like machine learning and artificial intelligence in healthcare. It’s no secret that healthcare has lagged behind many other areas in terms of its adoption of technology. It’s been far easier to order a meal on your phone than it has been to speak to a physician. COVID has changed a lot of that. We think it’ll continue to change. But we do think that technologies like machine learning and artificial intelligence will play bigger roles in the years to come.

But at the end of the day, what matters to us is a business’s ability to make money in a profitable way—generating high returns on invested capital and being able to reinvest those profits back into the business. It’s a fancy way of saying quality compounding. Within that construct, healthcare’s fabulous. You’ve got a lot of innovation, you’ve got inelastic demand and you have pricing power. You have profitability and strong reinvestment rates. So, we think. regardless of the market environment, investors should have exposure to healthcare.

Vinay Thapar
Portfolio Manager and Senior Research Analyst—US Growth Equities and International Healthcare Portfolio

Note to All Readers: The information contained here reflects the views of AllianceBernstein L.P. or its affiliates and sources it believes are reliable as of the date of this video. AllianceBernstein L.P. makes no representations or warranties concerning the accuracy of any data. There is no guarantee that any projection, forecast or opinion in this material will be realized. Past performance does not guarantee future results. The views expressed here may change at any time after the date of this video. This video is for informational purposes only and does not constitute investment advice. AllianceBernstein L.P. does not provide tax, legal or accounting advice. It does not take an investor’s personal investment objectives or financial situation into account; investors should discuss their individual circumstances with appropriate professionals before making any decisions. This information should not be construed as sales or marketing material or an offer or solicitation for the purchase or sale of any financial instrument, product or service sponsored by AllianceBernstein or its affiliates.

Related Insights